Efficacy of Iocide Oral Rinse Against Gingival Inflammation

NCT ID: NCT01782170

Last Updated: 2013-08-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2014-05-31

Brief Summary

The purpose of this study is to explore the efficacy of Iocide oral rinse in a human clinical trial of gingivitis. Iocide oral rinse will be evaluated against a placebo rinse. Indices for gingivitis, plaque and bleeding will be scored and blood tests will be performed to determine the effect of the antimicrobial oral rinse on relative levels of biological markers of inflammation.

Conditions

Gingivitis; Investigation of Biological Markers of Inflammation

Keywords

Gingivitis; Biomarkers; Biological Markers of Inflammation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Iocide Oral Rinse

Iocide Oral Rinse once daily 30 second rinse for 24 weeks

Group Type: ACTIVE_COMPARATOR

Iocide Oral Rinse

Intervention Type: DRUG

Placebo Control

Once daily 30 second rinse for 24 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Iocide Oral Rinse

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

Iocide Oral Rinse - once daily 30 second rinse for 24 weeks

Eligibility Criteria

Inclusion Criteria

• Males or non-pregnant females of at least 18 years of age, and in good general health, as determined by Investigator;
• Have at least 16 natural, gradable teeth and good dental health, as determined by Investigator;
• Have > 25% sites with Gingival Index (GI) scores of > 2 at Visits 1 and 2;
• Have Plaque Index (PI) scores of > 1 on > 50% of sites;
• Use of effective method of contraception for the duration of the study or permanently sterilized;
• Able and willing to comply with study requirements including following instructions on study treatment and returning for follow-up visits as required by the protocol;
• Have full understanding of all elements of, and signature and dating of the written informed consent prior to the initiation of protocol specified procedures;
• Females with childbearing potential must have a negative pregnancy test before and during the study period. Sexually active females must be using an effective form of birth control or abstinence. These methods include oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrol implants (Norplant®), medroxyprogesterone acetate injections (Depo-provera®) or contraceptive foam with a condom.

Exclusion Criteria

• History, or current evidence, of any significant acute or chronic subject-reported medical or psychiatric condition that, in the opinion of the Investigator, would render examination difficult or invalid or prevent the subject from active study participation;
• ≤24% of sites with GI score >2;
• Thyroid peroxidase antibody (TPOab) positive >34;
• Screening serum level of thyroid stimulating hormone (TSH) <0.45 or >4.5;
• Treatment with antibiotic within the one (1) month period prior to the screening examination;
• History of heart murmur, history of rheumatic fever, valvular disease, prosthetic implant or any other condition requiring antibiotic premedication;
• History of thyroid disease;
• Purported sensitivity or allergy to iodine;
• Known sensitivity or allergy to shellfish;
• History of diabetes;
• History of autoimmune disease;
• Gross oral pathology (periodontal disease, rampant caries, tissue damage created by poor oral care or treatment, soft or hard tissue tumors) that, in the opinion of the Investigator, could influence the outcome of the study;
• True periodontal pockets of > 5 mm and/or visible recession indicative of attachment loss;
• Current signs or symptoms of mucosal tissue ulcerations or inflammation, or canker sores;
• Presence of orthodontic appliances or any removable appliance that impinges on the oral tissues being assessed;
• History of early onset periodontal disease or acute necrotizing ulcerative gingivitis;
• Subject reported history in past 6 months or current alcohol abuse that, in the opinion of the Investigator, could influence the outcome of the study;
• Subject reported history of last past 6 months or current drug abuse;
• Chronic treatment (2 weeks or more) with any medication known to affect periodontal status (including phenytoin, calcium antagonists, cyclosporine, coumarin, non-steroidal antiinflammatory drugs, and aspirin) within 1 month of the screening examination. All other medications for chronic medical conditions have been initiated at least 3 months before enrollment;
• Current use of a statin or the use of a statin within the past sixty (60) days of screening;
• Concomitant therapy with another investigational drug or device without prior approval from the Sponsor within four weeks prior to Visit 2 (Study Day 1);
• Concomitant endodontic or periodontal therapy other than prophylaxis in the past six (6) months;
• Females with childbearing potential with a positive pregnancy test, pregnant or nursing mothers, suspected pregnancy, or intention to become pregnant during the study;
• Residence in the same household as a subject already enrolled in the study (inclusion may create blinding and/or compliance issues);
• Unable and unwilling to comply with the informed consent process, to meet study requirements including following instructions on study intervention, and to return for follow-up visits as required by the protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

University of Kentucky

OTHER

Sponsor Role: collaborator

Biomedical Development Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dolphus R Dawson III, DMD, MS

Role: PRINCIPAL_INVESTIGATOR

University of Kentucky

Locations

University of Kentucky, Center for Oral Health Research, College of Dentistry

Lexington, Kentucky, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Hailey Gallivan, CCRP

Role: CONTACT

Phone: 859-323-4923

Email: hbwils00@uky.edu

Karl McCloskey

Role: CONTACT

Phone: (361) 442-7491

Email: mccloskey@biodevcorp.com

Other Identifiers

R44HL101821

Identifier Type: NIH

Identifier Source: secondary_id

View Link

UK12-0972-F2L

Identifier Type: -

Identifier Source: org_study_id